Ultragenyx Pharmaceutical Inc. Stock
Heavy losses for Ultragenyx Pharmaceutical Inc. today as the stock fell by -€0.700 (-3.430%).
With 24 Buy predictions and not a single Sell prediction Ultragenyx Pharmaceutical Inc. is an absolute favorite of our community.
With a target price of 55 € there is potential for a 179.19% increase which would mean more than doubling the current price of 19.7 € for Ultragenyx Pharmaceutical Inc..
Pros and Cons of Ultragenyx Pharmaceutical Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
M***** P*******
Cons
?
B****
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Ultragenyx Pharmaceutical Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | -3.430% | 2.073% | 3.141% | -33.893% | 17.262% | -42.398% | -77.225% |
| Ionis Pharmaceuticals Inc. | -1.960% | -1.110% | -0.804% | 169.073% | -5.650% | 87.980% | 80.264% |
| United Therapeutics | -1.530% | -0.429% | 3.615% | 96.730% | 14.042% | 134.957% | 184.971% |
| Novocure Ltd | 1.510% | -1.181% | -17.043% | -37.089% | -20.300% | -84.943% | -91.850% |
Comments
Ultragenyx Pharmaceutical (RARE) had its price target lowered by JPMorgan Chase & Co. from $120.00 to $74.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $128.00 to $79.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) had its price target lowered by analysts at HC Wainwright from $60.00 to $50.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
News
Why Ultragenyx Pharmaceutical Stock Is Bouncing Back Today
While Ultragenyx Pharmaceutical (NASDAQ: RARE) provided the market with disappointing news yesterday -- shares plunged more than 42% -- it appears that investors aren't completely writing off the
Why Ultragenyx Pharmaceuticals Stock Is Plummeting Today
Heading into 2026 on an inauspicious note, Ultragenyx Pharmaceuticals (NASDAQ: RARE), a pharmaceutical company specializing in treatments for rare and ultra-rare genetic diseases, announced